Skip to main content

Table 1 Patient and tumor characteristics

From: A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

Characteristics

Arm A(EV) = 54

Arm B(PLD/V) = 50

 

No.

%

No.

%

Age, years

  

   Median

63

61

   Range

27-70

35-69

Pre/Postmenopausal

10/44

9/41

Median ECOGPS (range)

1(0-3)

1(0-3)

*HR status

    

   Positive

39

72.2

32

64.0

   Negative

13

24.1

15

30.0

   Unknown

2

3.7

3

6.0

HER-2 status

    

   Positive

    

   Negative

    

   Unknown

    

Prior adjuvant chemotherapy**

20

37

21

42

Prior hormonal therapy

    

   Adjuvant

35

64.8

30

60

   Advanced

10

18.5

11

22

Disease free-interval (years)

    

   < 1

10

 

11

 

   1-5

30

 

28

 

   >5

14

 

11

 

Dominant disease site

    

   Viscera

40

74.0

32

64.0

   Bone

11

20.4

9

18.0

   Soft tissue

3

5.6

9

18.0

Number of disease site

    

   1

23

42.6

23

46.0

   2

23

42.6

18

36.0

   ≥ 3

8

42.6

9

18.0

  1. * HR: hormonal receptor status
  2. ** not including anthracyclines or vinka alkaloids
  3. EV: epirubicin/vinorelbine; PLD/V: pegylated liposomal doxorubicin/vinorelbine